文献类型：期刊文献

英文题名：On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks

作者：Fu, Yun[1];Liu, Peng[2];Chen, Meng[1];Jin, Tongxia[1];Wu, Huijing[1];Hei, Mingyang[1];Wang, Congrong[3];Xu, Yufang[1];Qian, Xuhong[1];Zhu, Weiping[1]

机构：[1]East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai Key Lab Chem Biol, 130 Meilong Rd, Shanghai 200237, Peoples R China;[2]Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Shanghai Key Lab Diabet, 600 Yishan Rd, Shanghai 200233, Peoples R China;[3]Tongji Univ, Sch Med, Shanghai Peoples Hosp 4, Dept Endocrinol & Metab, Shanghai 200434, Peoples R China

年份：2022

卷号：605

起止页码：582

外文期刊名：JOURNAL OF COLLOID AND INTERFACE SCIENCE

收录：;EI(收录号：20213110707741);WOS:【SCI-EXPANDED(收录号:WOS:000704300000008)】；

基金：This work was supported by National Natural Science Foundation of China(Grants 21878088, 21476077, 82070913), Key projects of Shanghai Science and Technology Commission (18DZ1112703), Shanghai Science and Technology Development Funds(20ZR1446000) and Research start-up fund from Shanghai Fourth People's Hospital(sykyqd01801).

语种：英文

外文关键词：Phenylboronic acid; Microneedle patch; Controlled insulin delivery; Glucose responsive

摘要：Diabetes is a metabolic disease that is affecting an ever-increasing number of people worldwide, resulting in increased burdens on healthcare systems and societies. Constant monitoring of blood glucose levels is required to prevent serious or even deadly complications. One major challenge of diabetes management is the simple and timely administration of insulin to facilitate consistent blood glucose regulation and reduce the incidence of hypoglycemia. With this research, we construct an insulin delivery system, the delivery system is comprised of phenylboronic acid based fluorescent probes, which is used as glucose responsive linkers, mesoporous silica nanoparticles providing an insulin reservoir, and zinc oxide nanoparticles used as gate keepers. The system with glucose sensitive responsive linker exhibits controlled release of insulin under high glucose concentrations, providing prolonged blood glucose regulation and no risks of hypoglycemia. Furthermore, the system is combined with a hyaluronic-acid based microneedle patch, which exhibit efficient skin penetration for transdermal delivery. With our sys-tem, the nanoparticles provide outstanding in vivo glucose regulation when administrated by subcuta-neous injection or via transdermal microneedle patch. We anticipate that our biocompatible smart glucose responsive microneedle patch (SGRM patch) will facilitate the development of clinically useful systems. CO 2021 Elsevier Inc. All rights reserved.